We are extremely excited to announce that Matricelf has been selected as a “one to watch” for the Nature Research Spinoff Prize. This reward and recognition will bring Matricelf one step closer to becoming a global leader in personalized regenerative medicine .
The Spinoff Prize has been established by Nature Research in partnership with Merck KGaA, to showcase and celebrate global excellence in the commercialization of research through the creation of Spinoff companies. The prize aims to provide visibility and support for international academic entrepreneurs and their recently formed companies, worldwide. The competition judges select 32 promising companies as the “ones to watch”. Matricelf has been selected as one of them, as announces and featured Nature’s special report issued June 30.
Matricelf, developed by Prof. Tal Dvir, is a technological platform for regenerative medicine using autologous matrix and cells implants for a variety of medical conditions. The technology that was recently licensed from Ramot enabled Prof. Tal Dvir and his group at the Tel Aviv University to print the first ever 3D printed heart.
Matricelf is a spin-off company of Ramot, the technology-transfer company of Tel Aviv University.